உற்பத்தித் திறன் சேர்ப்பு
டீல்
டீல் மதிப்பு₹20 கோடி
டீல் vs வணிகம்Capex of ₹20 Cr represents 7.8% of TTM revenue (₹258 Cr) and 11.2% of net worth; expands tube capacity by 14.94%.
சொந்த வருவாயுடன் ஒப்பிடும் அளவு0.08×
செயல்படுத்தும் காலம்0.75 ஆண்டு
அடிப்படை தரம்B
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)8.5% / 13.5%
EPS உயர்வு12.0%
அப்சைடு பேஸ் / புல் / பேர்38.0% / 75.0% / -22.0%
கால எல்லை12-18 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம் (22 செப். 2026)₹44.0
சமீபத்திய முடிவு விலை (13 நவ. 2026)₹52.27
தொடங்கியதிலிருந்து வருமானம்+18.8%
α vs Smallcap 250+20.1%
α vs சொந்தத் துறை90+ நாட்கள் வைத்திருந்த பிறகு மட்டுமே காட்டப்படும் — பேக்கேஜிங் இடைநிலை +5.2%, முதிர்ச்சியடைந்த 32 பரிந்துரைகளின் அடிப்படையில்
நேர்மறைகள்
- High capacity utilization of 90% directly justifies brownfield tubing addition, lowering under-utilization risk.
- Internal accrual funding: ₹20 Cr capex funded without external debt, keeping D/E lean at 0.12.
- Strong top-line acceleration evidenced by Q1 FY27 revenue growing 45.5% YoY to ₹80.52 Cr.
- Strong parentage support from Nirma Group (61.57% promoter holding) providing liquidity safety and operational synergies.
அபாயங்கள்
- Raw material volatility: Severe exposure to polymer and aluminum price spikes which directly squeeze operating margins if pass-through lags.
- Working capital drag: Gross Current Assets at 156 days indicate elevated working capital lock-up as scale increases.
- Valuation premium: P/E of 23.7x sits at a premium to peer median of 17.6x, reducing multiple expansion headroom.
- Historical one-off distortions: FY25 net profit was skewed heavily by deferred tax/one-off gains, requiring scrutiny of recurring operating cash flow.
நிர்வாக எச்சரிக்கைகள்
- Repeated extension of ₹7.67 Cr preference share redemption period by 5 years (approved Aug 2026).
- Outstanding large contingent liability settlement noted in qualitative disclosures.
முழு AI சுருக்கம்
1. Executive Summary & Catalyst Assessment
On September 21, 2026, Shree Rama Multi-Tech Limited (SHREERAMA) announced the commercial commencement of a new tubing machine at its Moti-Bhoyan facility. The brownfield capex of ₹20 Cr adds 1.15 crore tubes per month to an existing base of 7.70 crore tubes per month (+14.94% capacity). Existing lines operated at 90% utilization, providing clear commercial rationale and mitigating idle-capacity risk. This follows a previous addition of 45 lakh tubes/month in June 2026, confirming an aggressive brownfield debottlenecking strategy.
2. Ramp-Aware Catalyst Financial Math
- Capacity Dynamics: Tubing capacity expands from 7.70 Cr to 8.85 Cr tubes/month (~1.06 billion tubes annually, up from ~924 million).
- Revenue Impact:
- TTM Revenue is ₹258 Cr. Assuming the tube division constitutes the core volume driver and current lines operated at 90% utilization, the 14.94% capacity expansion unlocks incremental steady-state revenue of ~₹35-38 Cr.
- Execution Ramp: Commercial operations commenced immediately (21-Sep-2026) with full stabilization targeted across Q3 FY27.
- Year 1 Uplift: Factoring a 60-70% ramp over the next 12 months, incremental revenue is estimated at ₹22 Cr (+8.5% on TTM base).
- Steady-State Uplift: Full 85-90% utilization achieved by FY28 adds ~₹35 Cr (+13.5% uplift).
- Operating Leverage & EPS Uplift:
- At steady-state operating profit margin (OPM) of ~16.5% (in line with TTM 16.8%), incremental EBITDA is ~₹5.8 Cr.
- Deducting depreciation (~₹1.6 Cr on ₹20 Cr plant & machinery at 8%) and interest (negligible; internal accrual funded), PBT addition is ~₹4.2 Cr.
- At a standard 25% corporate tax rate, incremental PAT is ~₹3.1 Cr.
- On current TTM PAT of ₹25.7 Cr (TTM EPS ₹1.84 on ~13.9 Cr shares), incremental PAT lifts baseline EPS by ₹0.22/share (+12.0% uplift to ~₹2.06 EPS).
3. தொழில்துறைச் சூழல் & தர மதிப்பீடு
- Industry & Execution: Packaging has moderate capital intensity and low-to-medium execution complexity for brownfield tube machinery additions. Structural Indian packaging growth is 8-11% CAGR driven by oral care, pharma, and personal care laminated tube penetration.
- Balance Sheet & Returns: Low leverage (Debt ₹22 Cr, D/E 0.12), healthy ROCE of 18.0%, and backing by Nirma Group (61.57% promoter holding) provide robust financial stability.
- Operating Vulnerabilities: Gross Current Assets of 156 days reflect high working capital needs. Sensitivity to polymer/aluminum commodity cycles remains high.
4. Valuation & Calibrated Scenarios (12-18 Month Horizon)
- Current Base: Price ₹43.7, TTM EPS ₹1.84, trailing P/E 23.7x (vs peer median 17.6x).
- Base Case (+38%): Execution proceeds as planned; FY28 EPS reaches ₹2.25 driven by combined organic industry growth and new capacity; multiple derates slightly to 27x FY28 EPS, yielding a target price of ~₹60.3.
- Bull Case (+75%): High customer uptake in premium pharma/cosmetic tubes expands OPM toward 18.5%; FY28 EPS expands to ₹2.65; P/E re-rates to 29x on Nirma group backing and consistent growth; target price ~₹76.8.
- Bear Case (-22%): Polymer cost inflation crimps OPM to 12%; extended working capital cycles and contingent liability settlement obligations hit cash flow; FY28 EPS stagnates near ₹1.70; multiple derates to peer parity (20x); target price ~₹34.0.
5. Final Verdict
SHREERAMA is classified as POSSIBLE (Score: 62/100). The capex is practical, well-funded via internal cash flows, and supported by high pre-existing utilization. However, its 15% capacity uplift is an incremental compounding driver rather than an explosive mega-order, and elevated trailing valuation (23.7x P/E) tempers immediate re-rating runaway.
2026-09-21 நிலவரப்படி பகுப்பாய்வு (விலை ₹43.66) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
